[Outcome of XXXX treated with high doses of @entity1169 ].

@entity1 @entity1121 @entity943 @entity1169
Twenty-five @entity1 with @entity1121 confirmed by clinical, echocardiographic and haemodynamic investigations were treated with high dose @entity1169 (320 to 800 mg/day, average 420 mg/day) and assessed after an average follow-up period of 25 months. The effects of treatment were assessed by interrogation in all @entity1 and by exercise testing before and after @entity1169 in 19 cases. Comparative echocardiographic (21 @entity1 ) Holter (20 @entity1 ) and catheter studies (14 @entity1 ) were also performed. The cardiovascular mortality rate during the study period was nil. All @entity1 were symptomatic before treatment; 9 became asymptomatic and 13 @entity1 were improved, the average functional score decreasing from 5.16 +/- 2.15 to 2.28 +/- 1.49 (p less than 0.001). The persistence of severe symptoms led to withdrawal of the beta-blocker in 2 cases. There was a parallel improvement in maximal work capacity during exercise stress testing (96 +/- 27 watts vs 117 +/- 30 watts, p less than 0.01). A resting intraventricular pressure gradient was recorded in 12 of the 14 @entity1 undergoing repeat catheter study which decreased after @entity1169 from an average of 66.75 +/- 32.72 mmHg to 42.75 +/- 37.6 mmHg (p less than 0.05). Left ventricular end diastolic pressures remained unchanged. The change in pressure gradient did not correlate with the symptomatology and there were no associated echocardiographic changes. The Holter monitoring did not show any improvement of ventricular hyperexcitability under @entity1169 : the number of @entity1 with complex @entity943 remained unchanged (7 @entity1 ).(ABSTRACT TRUNCATED AT 250 WORDS)
